ArQule, Inc. (NASDAQ:ARQL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “

Separately, ValuEngine downgraded ArQule from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

ArQule (NASDAQ:ARQL) traded up 0.442% during midday trading on Thursday, hitting $1.135. 327,305 shares of the stock traded hands. The firm’s 50 day moving average is $1.10 and its 200-day moving average is $1.13. The stock’s market capitalization is $80.78 million. ArQule has a 12-month low of $0.92 and a 12-month high of $1.82.

ArQule (NASDAQ:ARQL) last posted its quarterly earnings results on Friday, August 4th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. ArQule had a negative return on equity of 135.68% and a negative net margin of 482.44%. During the same period in the prior year, the firm earned ($0.07) earnings per share. On average, analysts anticipate that ArQule will post ($0.43) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “ArQule, Inc. (ARQL) Downgraded by Zacks Investment Research to Hold” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/arqule-inc-arql-downgraded-by-zacks-investment-research-to-hold.html.

An institutional investor recently raised its position in ArQule stock. Northern Trust Corp boosted its stake in ArQule, Inc. (NASDAQ:ARQL) by 0.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 154,513 shares of the biotechnology company’s stock after purchasing an additional 1,385 shares during the quarter. Northern Trust Corp owned about 0.22% of ArQule worth $192,000 at the end of the most recent reporting period. 60.95% of the stock is owned by hedge funds and other institutional investors.

ArQule Company Profile

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Get a free copy of the Zacks research report on ArQule (ARQL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.